Integrin αvβ1 inhibitor (a small molecule, PLN-1474) is in a Phase 1 trial for MASH fibrosis (Slack et al. 2022) and GDF8/Activin A inhibitor (K065) is in a Phase 1 trial for obesity and muscular dystrophy (Keros, 2024). The gene discussed is MSTN; the disease is metabolic dysfunction-associated steatohepatitis.